Verve Ventures invests in missionary entrepreneurs working on improving human health. Driven by hardware automation, precision control and engineering, and machine learning (ML), we believe operating at the intersection of biology and engineering will reduce costs as well as improve the outcomes for patients. We invest in companies working on affordable diagnostics and monitoring tools, offering personalized treatment, and developing novel therapies and drugs based on more efficient design.
What we invest in
AI ENABLED
PRECLINICAL &
CLINICAL
ACCELERATION
We invest in companies led by teams with experience in clinical setting and or drug development, with a strong data moat and a business model enabling to develop partnerships with pharma.
- AI driven drug discovery
- Personalised Medicine
- Enabling tech for pre-clinical and clinical trial
- Pre-clinical translation model discovery
NEXT-GEN
DIAGNOSTICS,
THERAPEUTICS &
MONITORING
We invest in companies that bridge the gap between patients and healthcare through AI-enabled digital solutions, improving care delivery, accessibility, and addressing areas of high unmet medical need.
- AI-Powered Diagnostics and Imaging Tools
- Digital Therapeutics (DTx) & Virtual Care
- Remote Patient Monitoring (RPM)
- Healthcare Workforce Augmentation
NEXT-GEN
BIOLOGICS &
BIOMANU-
FACTURING
We invest in companies with breakthrough scientific discoveries that can create flexible, scalable platforms – reducing the risk of investing in traditional single-asset Biotechs.
- Platform technologies for next-gen biologics design
- Biomanufacturing
- Synthetic Biology & Programmable Biologics
- Scalable delivery technologies for advanced therapeutics
500K-2mio EUR
Initial ticket size
(Pre-) Seed & Series A
Stages
Europe
Geography
Portfolio entrepreneurs about Health & Bio
“Patients would be more than happy to take a capsule instead of injecting themselves. This is what I want to achieve with Biograil, bring relief to these patients by offering an oral delivery route instead of injections. Our strongest asset is simplicity. Our solution uses just a few elements, and it enters the wall of the intestine with the pressure the body creates itself.”
OUR HEALTH & BIO PORTFOLIO
Limula: Unlocking the full potential of cell therapies with automation
Cell therapy manufacturing’s cost, complexity, and scalability challenges have restricted patient access to these life-saving treatments for too long. In this interview, Luc Henry discusses how Limula’s innovative device unlocks their full potential. The conversation also explores the broader…
Memo Therapeutics finds ultra-rare antibodies
Memo Therapeutics AG is a late-stage biotech company developing best-in-class therapeutic antibodies based on natural immunity in elite responders to transform the lives of patients with viral infections and cancer. Their lead program, potravitug, currently in Phase II development, is the most…
Health & Bio
Investment TEAM
The members of our investment team are scientists, engineers and investors. These team members focus on Techbio investments:
Steffen Wagner
Xavier Mesnier
Rebecca Laurent
Bernardo Delarue Bizzini
WITH US, YOU CAN CO-INVEST WITH THEM
Verve's investor network
We’re not alone in our mission. We co-invest with some of the most sophisticated venture capital firms focusing on industrial change. And our network of qualified private investors can co-invest with us alongside these firms. If you want to contribute to solving the challenges of human health with your health & bio investments, you should join us.
Articles about Health & Bio
21.08.2024
“We are uniquely positioned to succeed”
Biograil CEO Karsten Lindhardt discusses how his company's experience, partnerships, and approach will transform drug delivery and improve patient lives worldwide.
21.05.2024
“Entrepreneurship is like soccer, not tennis.”
Three-time founder turned venture capitalist Iñaki Berenguer now invests in extending the lives of people and the planet. In this interview, he shares lessons on entrepreneurship, what he learned…
19.03.2024
“Biotech is a wonderfully complex industry”
Industry veteran Erik van den Berg joined Verve’s portfolio company Memo Therapeutics right after it raised CHF 25 million in late 2023. The Company is now at a very exciting stage in its…
Frequently Asked Questions
With over 10 years of experience and 30+ investments under the healthcare umbrella, and driven by the large network of LPs and portfolio founders, we are one of the few European investors with the technical, commercial, and operational expertise in growing the companies, and supporting on market entry, expansion, technical scalability, biopharma partnerships, and fundraising.
While we do not invest in single asset or single indication therapeutics, we have invested and will continue to invest in platform technologies that allow for development of multiple assets applicable across multiple indications or allow for licensing of the technology for co-developing assets with biopharma.
Yes! We have a mix of hardware and software only companies in our portfolio. However, we believe in owning the entire value chain and that real differentiation comes from building at the intersection of multiple disciplines.
With over 10 years of experience in high tech investments and technical founding teams, we understand the specific challenges and opportunities of scaling such startups. We have built an extensive network of advisors, co-investors, partners and potential clients that is at your disposal.As DeepTech investors we understand the timelines in TechBio and are able to provide capital for the long run. We focus on long-term company building and value generation rather than short-term optimization.
Yes, you could find us in local health & bio events in the EU and the UK, and the large healthcare conferences (e.g., JPM, LSX). However, you do not need to wait for an in person meeting. You are welcome to contact our health & bio team with a brief summary about yourself and your company.
The right timing for a funding round can vary depending on your specific business. Generally, being able to show an MVP or even a full product, first market traction through LOIs or POCs, as well as a well-functioning core team and ideally product market fit are decisive factors.We’d like to get to know you and your team early on. Therefore, we are also happy to start an initial conversation without first market traction or if you are not fundraising at the moment. We suggest reaching out to the one of the health & bio team members above.
We co-invest with some of the most sophisticated venture capital firms focusing on industrial change. And our network of qualified private investors can co-invest with us alongside these firms. If you want to contribute to solving the challenges of human health with your health & bio investments, you should join us.































